Photo credit: Commons

1. Regeneron Pharmaceuticals CEO Leonard Schleifer and Pfizer CEO Ian Read argued about the role pharma has played in fueling the drug-pricing debate at the Forbes Healthcare Summit. After Read said that drug costs have remained the same percentage of U.S. healthcare expenses for two decades, Schleifer countered: “You’re not entitled to a fraction of the GDP.” (Bloomberg)

2. Mylan CEO Heather Bresch defended the company in light of the EpiPen pricing controversy while speaking at the Forbes Healthcare Summit. Bresch noted that the company used some of the money from its price increases to improve the autoinjector. (MM&M)

3. Pfizer and IBM will partner to use Watson to help the drugmaker discover new cancer immunotherapies. Watson is expected to help Pfizer researchers select which experimental therapies are the most promising for development. (Fortune)

4. U.K. cost watchdog NICE endorsed Merck’s immuno-oncology drug Keytruda for use as a treatment for non-small cell lung cancer. NICE noted that Merck must continue to discount Keytruda in order for it to be endorsed by the organization’s guidelines. (Pharma Times)

5. A multiple-myeloma treatment developed by Bluebird Bio and Juno Therapeutics showed strong efficacy in a small trial. Some patients had no detectable traces of blood cancer in their body after treatment. (Reuters)